Please liaise with your IT department to ensure you can save PDFs before completing the form.
MHRA has created a new international recognition route for medicines utilising pre-existing approvals from Australia, Canada, the European Union, Japan, Switzerland, Singapore and the United States. This new framework will support patients in the UK with expedited access to safe and effective medicines that have been approved by trusted regulatory partners. From 1 January 2024, international recognition will sit alongside MHRA’s current national procedures.
Webinar
The MHRA webinar held on 23 November 2023 provided potential applicants with the opportunity to increase their knowledge and understanding of the guidance on the International Recognition Procedure. A follow-up webinar in April 2024 presented post-launch updates and latest information about the new route.
Updated 'IRP initial validation checklist' after reports of users experiencing problems with some of the check-boxes.
30 July 2024
Updated 'IRP lifecycle validation checklist'.
9 July 2024
Updated International Recognition Procedure and eCTD guidance
24 May 2024
Updated guidance documents: International Recognition Procedure and International Recognition Procedure - supplementary information, and added new webinar link
8 April 2024
Multiple updates to 'supplementary information'.
5 January 2024
Added link to Fees Calculator.
20 December 2023
Added recording of 'MHRA International Recognition Webinar November 2023'.
8 December 2023
Added submission dates for Recognition B which align with CHM dates for New Active Substances (NAS).
20 November 2023
Added guidance on the Eligibility Checker and submitting your Marketing Authorisation application, IRP Product Lifecycle & eCTD guidance for MAs and Lifecycle.
6 November 2023
Additional guidance added to address common queries about the International Recognition Procedures.